Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Modern Systemic Therapies for Psoriasis in Active-Duty German Soldiers: A Retrospective Single-Center Study of Treatment Outcomes and Service-Wide Operational Burden.

Created on 16 Nov 2026

Authors

Atakan Jordan, Georgios Kokolakis, Staffan Vandersee

Published in

Psoriasis (Auckland, N.Z.). Volume 16. Pages 647894. Epub Nov 11, 2026.

Abstract

Several armed forces treat psoriasis as a categorical barrier to service, and systemic therapy can preclude enlistment or restrict deployment. These standards predate interleukin-17 and interleukin-23 inhibitors. We assessed efficacy, safety and drug survival of modern versus conventional systemic therapies in active-duty soldiers, and the psoriasis-attributable operational burden in the German Armed Forces.
Single-center retrospective cohort study. Of 142 active-duty soldiers with psoriasis seen in 2019-2023, 77 had received systemic therapy between 2004 and 2023 (first line 49 modern, 28 conventional, 127 treatment cycles in total). Endpoints were estimated Investigator Global Assessment (IGA) at initiation and at the last visit on first-line therapy, adverse events (CTCAE version 6.0), and drug survival (Kaplan-Meier and Cox regression). Operational outcomes came from four service-wide registries not linked to the cohort.
Mean estimated IGA improved by 2.0 points under first-line modern versus 0.8 points under conventional therapy (P < 0.001), and complete clearance (IGA 0) was reached by 38/49 (78%) versus 1/28 (3.6%) (P < 0.001). Adverse events caused discontinuation in 2/97 (2.1%) modern versus 14/30 (46.7%) conventional cycles (P < 0.001). No grade 3 or 4 laboratory abnormality occurred (0/60, 95% CI 0-6.0%). Modern therapy was associated with less discontinuation or switching (first-line hazard ratio 0.17, 95% CI 0.08-0.33; calendar-year adjusted 0.10, 95% CI 0.05-0.23). Service-wide, no declaration of permanent unfitness for service due to psoriasis was recorded over 20 years, and psoriasis caused 4 of 7096 repatriations (0.056%). Of 87 diving-fitness assessments documenting psoriasis, among 15,718 in total, one (1.1%) was negative, owing to psoriatic arthritis.
In this single-center military cohort, modern systemic therapies were associated with higher clearance, fewer adverse-event discontinuations and longer drug survival. Service-wide data showed a low observed psoriasis-attributable operational burden. These findings support giving demonstrated treatment response greater weight in individualized military fitness assessment.

PMID:
43036711
Bibliographic data and abstract were imported from PubMed on 16 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 10
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement